TORL BioTherapeutics names Mark Alles as CEO

12 January 2024

California, USA-based biotech start-up TORL BioTherapeutics has appointed of Mark Alles, currently executive chairman, to the additional post of chief executive (CEO).

Mr Alles is the former chairman and CEO of Celgene, which US pharma major Bristol Myers Squibb (NYSE: BMY) acquired for $74 billion in 2019. He has over 35 years of biopharmaceutical experience and an outstanding record of driving innovation and growth at multiple companies focused on hematology and oncology.

Mr Alles succeeds Dave Licata, TORL co-founder and previous CEO, who successfully led the company through the initiation of five Phase I clinical trials testing antibody-drug conjugates (ADCs) against four cancer targets and led the closing of a $158 million Series B financing in April 2023, and who will continue as a board member, president, and has been appointed chief financial officer (CFO).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK